<DOC>
	<DOCNO>NCT01711853</DOCNO>
	<brief_summary>The study conduct prospective , open label trial . It design evaluate pharmacokinetic/pharmacodynamic coagulation parameter safety dabigatran etexilate patient chronic kidney disease .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Pharmacodynamics Dabigatran Etexilate Patients With Stable Severe Renal Disease .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age 18 year old 2 . Impaired renal function define stable CockcroftGault and/or actual creatinine clearance 1530 ml/min last 3 month study participation . 3 . The single use either aspirin Vitamin K Antagonists 4 . Provision informed consent . Exclusion criterion : 1 . Unstable renal function Creatinin Clearance &lt; 15mL/min 2 . Patients treat two platelet aggregation inhibitor 3 . Use indication therapeutic heparin 4 . Patients prosthetic heart valves 5 . Haemorrhagic disorder bleed diathesis 6 . Platelet count &lt; 100 109/L ) screening last 30 day screen . 7 . Participation another drug trial last 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>